Navigation

Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]

Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome (to be included in a review of TA32 - subject to review proposal consultation)

Status: Suspended
Expected date of issue: TBC
Referral date: July 2009
Process: MTA
Topic area:
  • Central nervous system
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Project manager: TBC
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date

 

Update

 

1 April 2010

 

This technology appraisal was formally referred to the Institute as part of the 21st wave work programme. The remit was as follows:

To appraise the clinical and cost effectiveness of interferon beta-1b, interferon beta-1a and glatiramer acetate within their licensed indications for the treatment of single demyelinating event with clinically isolated syndrome (to be included in a review of TA32).

TA32 is currently regarded as ‘static’ guidance and the Institute is of the opinion that this is still appropriate.  As a result, this appraisal will not commence at this time due to the remit specifically indicating that it should be included in a review of TA32.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

Top


 

Key documents

This page was last updated: 02 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.